Editor's Note: Green and red arrows refer to intraday stock price movement.
NEW YORK ( TheStreet) -- CHANGE IN RATINGS
Baidu (BIDU) rated new Buy at Jefferies. $200 price target. Company is a market leader with limited competition.
Comerica (CMA) rated new Market Perform at Morgan Keegan. $38 price target. Visibility remains low for potential loan growth.Fastenal (FAST) upgraded at UBS from Neutral to Buy. $72 price target. Estimates also boosted, as sales growth can drive margin expansion. Henry Schein (HSIC) upgraded at Goldman to Buy, Goldman Sachs said. $80 price target. Industry should benefit from improving macro trends. Intermune (ITMN) upgraded to Outperform at Wells Fargo. Expecting a more robust Esbriet launch. Perrigo (PRGO) upgraded at from Sell to Neutral, Goldman Sachs said. $80 price target. Company can move past the FDA issue and should continue to realize synergies from recent deals. Riverbed Technology (RVBD) upgraded at ThinkEquity from Hold to Buy. $48 price target. Guidance confirms recent checks that show demand can recover. Riverbed Technology (RVBD) upgraded at Oppenheimer from Perform to Outperform, Oppenheimer said. $40 price target. Company pre-announced to the upside, easing some demand concerns. Sirona Dental (SIRO) rated new Buy at Goldman. Company was also addded to the Conviction Buy list. Company is leverage to increased spending on high-tech equipment. $61 price target. Sunoco (SUN) downgraded at Benchmark from Hold to Sell, Benchmark Company said. $34 price target. Company is facing an unfavorable settlement for coke pricing. Dentsply (XRAY) rated new Neutral at Goldman Sachs. $39 price target. Stock is already pricing in improving industry growth.
End of report.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV